• 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>美国生物医药公司BioMarin收购Lead治疗公司

    正规十大时时彩网站: 美国生物医药公司BioMarin收购Lead治疗公司

    BioMarin2010年2月23日 19:27 点击:3948

    时时彩网络平台 www.qlgr.net 美国BioMarin Pharmaceutical

    Lead治疗公司被BioMarin收购,首付1800万美元股票
    美国生物医药上市公司BioMarin制药公司(Nasdaq:BMRN)表示,它计划用股票置换的方式收购位于加州San Bruno 市的Lead治疗药业公司。将以价值1800万美元的股票作为此项并购的首付。未来如果有药物得到上市批准,将获得高达9700万美元的后续支付。

    Lead治疗药业公司目前有一个口服治疗稀有癌症的药物LT-673正在临床前开发中,如果收购按照预期完成,该公司将在Lead治疗药业申报临床IND后,支付Lead药业股东1100万美元价值的股票。Lead治疗公司估计该药的IND申请将在今年年底前完成。

    BioMarin制药公司预计该交易将产生本年度1100万-1300万美元的运营开支和收购费用。在宣布此项并购的同时,BioMarin制药公司公布了今年的的财务预期。收入预计将3.84亿美元至4.05亿美元,同比2009年预计的3.13亿-3.27亿美元。今年的净收益预计为200万美元至1200万美元。

    Lead治疗药业公司创办于2007年4月,公司在San Bruno 圣布鲁诺和中国上海设有办事处,该公司是由帕帕斯风险投资公司,ProQuest投资和Mustang Ventures风险投资支持。它目前还有两个处于临床前研发阶段的产品LT-673和LT-29,这是治疗如金黄色葡萄球菌和链球菌病原体感染的抗生素。

    Lead治疗公司2007年成立后募集了1700万美元,如果假设投资者当时认购40%的股权,公司三年前的价值可能已是4250万美元了。尽管这次并购,这次并购,Lead治疗的投资者可能首先拿到少于1000万美元的股票。后面的股票和收益是多大,完全要看药物的临床数据。而且要等好多年。从这个意义上讲,这并不是一桩非?;愕穆蚵???赡躄ead治疗经过三年多的运营,后续资金会有问题。再融资可能未必会有好的估值,所以投资者乘“好”就收,走为上策。

    BioMarin新闻稿

    BioMarin to Acquire LEAD Therapeutics

     

    --Key Asset is LT-673, PARP Inhibitor for the Treatment of Genetically Defined Cancers --Conference Call and Webcast to Be Held Today at 5:00 p.m. ET

     

    NOVATO, Calif., Feb 04, 2010 /PRNewswire via COMTEX/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.

    "The acquisition of LEAD Therapeutics will augment our development pipeline of orphan therapeutics. With LT-673 we see a tremendous opportunity to apply our expertise in developing therapeutics for genetic diseases to the field of oncology by targeting cancers with defined genetic mutations that make them susceptible to treatment with agents such as LT-673. There are attractive opportunities to treat rare cancers with PARP-sensitive mutations, as a single agent and in combination with other DNA damaging agents, and to improve on PARP inhibitors currently in development for more common tumor types," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We remain centrally focused on our core commercial business, the launch of amifampridine for LEMS in Europe and our Phase 2 PEG-PAL and GALNS development programs. We can now also look forward to an IND filing for LT-673 by the end of 2010."

    Hank Fuchs, M.D., Executive Vice President and Chief Medical Officer of BioMarin added, "PARP inhibitors have shown impressive survival benefits in cancer patients with tumors that have defects in DNA repair or in combination with DNA damaging agents. There are many opportunities to achieve selective lethality with PARP inhibitors in both rare and more common cancers. LT-673 has been proven to be highly active in mouse xenograft models of human cancer and appears to have favorable properties, including potency, selectivity, and bioavailability."

    Under the terms of the stock purchase agreement, BioMarin will pay to the stockholders of LEAD $18 million upfront and will pay an additional $11 million upon acceptance of the IND filing (filing expected by the end of 2010), and up to $68 million for development and launch milestones for LT-673. As a result of this acquisition, BioMarin expects to incur approximately $11.0 to $13.0 million in operating expenses and acquisition related charges in 2010. Subject to customary closing conditions, the acquisition is expected to be completed by mid-February 2010.

    Conference Call Details

    BioMarin will host a conference call and webcast to discuss the acquisition of LEAD Therapeutics today, Thursday, February 4, at 5:00 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.BMRN.com.

    Date: February 4, 2010
    Time: 5:00 p.m. ET
    U.S. / Canada Dial-in Number: 800.299.9630
    International Dial-in Number: 617.786.2904
    Participant Code: 29296665
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 25068117

    About BioMarin

    BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse(TM) (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

    About LEAD Therapeutics

    LEAD Therapeutics began operations in April 2007 as a drug discovery company. LEAD has offices in San Bruno, California, and in Shanghai, China. Drug discovery programs are conducted through an extensive network of collaborations with contract research organizations in China and North America, including a strategic relationship with ChemPartner in Shanghai. LEAD currently has two programs in preclinical development: LT-673, a PARP inhibitor being developed for oncology indications and LT-29, a glycopeptide antibiotic for gram-positive infections, and drug discovery activities that include a Cyp17 inhibitor program for the treatment of castration resistant prostate cancer. LEAD is a private biopharmaceutical company whose investors include Pappas Ventures, ProQuest Investments and Mustang Ventures.

    Forward-Looking Statement

    This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of the development of LT-673, a poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of solid tumors and the expected completion of the transaction and the timing of such completion. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities, results and timing of current and planned preclinical studies and clinical trials related to such product; our ability to successfully manufacture the product; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

    BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

    Firdapse(TM) is a trademark of BioMarin Huxley Ltd.

    Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

        Contact:
    
        Investors                       Media
        Eugenia Shen                    Susan Berg
        BioMarin Pharmaceutical Inc.    BioMarin Pharmaceutical Inc.
        (415) 506-6570                  (415) 506-6594
    
    
    

    SOURCE BioMarin Pharmaceutical Inc.


     

    (来源: BioMarin )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 新捕鱼电玩城注册送分 凯旋门娱乐登录网址 德州扑克游戏官网 湖南幸运赛车开奖奖金 秒速时时彩哪里开奖 微信红包牛牛出千工具 体彩云南11选5开奖查询今天开奖结果 河南11选5开奖走势图一定牛 海南私彩票开奖时间 足彩预测软件app哪个好 3d开机号3d之家近十期 天尊 黑龙江时时开奖视频直播 时时彩稳赚10中8 时时彩投资一天稳赚